The abstract is read at the publisher; the summary is JClub's.
In the PALLAS phase III trial for stage II–III hormone receptor-positive breast cancer, developing high-grade neutropenia (grade ≥3) on palbociclib plus endocrine therapy is linked to better 5-year invasive disease-free survival than endocrine therapy alone.
- Why it matters: Prior PALLAS analyses found no overall benefit, but earlier evidence suggests neutropenia severity may reflect sensitivity to palbociclib and related cell cycle–targeted drugs.
- What they did: Patients on palbociclib were grouped by treatment-emergent neutropenia: high-grade neutropenia (maximum grade ≥3; absolute neutrophil count <1000/mm3) versus low-grade/no neutropenia (maximum grade ≤2), then compared with the endocrine therapy–alone arm for 5-year iDFS.
- The result: Endocrine therapy alone had inferior 5-year iDFS versus palbociclib+ET patients who developed high-grade neutropenia by cycle 6 (HR 1.19, 95% CI 1.01–1.40; p = 0.04), persisting after adjustment (HR 1.20, 95% CI 1.02–1.42; p = 0.03).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.